In humans, the GLP-1 receptor is expressed in the pancreas, lungs, brain, kidneys, stomach, and heart but not in the liver, skeletal muscle, or adipose tissue [27]
In endometrial scarring or post-surgical contexts, BPC-157s wound healing capabilities could accelerate tissue repair and reduce adhesions, potentially enhancing implantation potential
American pharmaceutical firm Eli Lilly similarly sought to halt compounded versions of its drugs Mounjaro and Zepbound, intended for diabetes and obesity treatment
Lifestyle change remains the foundation for all weight loss GLP-1 agonists like Wegovy and Saxenda are designed to be used for the chronic treatment of obesity, not something to be used in the short-term
Weight maintenance is part of our plan
Importantly, these effects persist throughout long-term treatment, avoiding the tolerance development and efficacy loss observed with some appetite suppressants